BR112012004697B8 - método para purificar um polipeptídeo compreendendo uma região ch2/ch3 - Google Patents

método para purificar um polipeptídeo compreendendo uma região ch2/ch3

Info

Publication number
BR112012004697B8
BR112012004697B8 BR112012004697A BR112012004697A BR112012004697B8 BR 112012004697 B8 BR112012004697 B8 BR 112012004697B8 BR 112012004697 A BR112012004697 A BR 112012004697A BR 112012004697 A BR112012004697 A BR 112012004697A BR 112012004697 B8 BR112012004697 B8 BR 112012004697B8
Authority
BR
Brazil
Prior art keywords
polypeptide
purifying
region
eluting
protein
Prior art date
Application number
BR112012004697A
Other languages
English (en)
Other versions
BR112012004697B1 (pt
BR112012004697A2 (pt
Inventor
Brown Arick
Nandini Radhamohan Asha
J Dowd Christopher
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012004697(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112012004697A2 publication Critical patent/BR112012004697A2/pt
Publication of BR112012004697B1 publication Critical patent/BR112012004697B1/pt
Publication of BR112012004697B8 publication Critical patent/BR112012004697B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

método para purificar um polipeptídeo compreendendo uma região ch2/ch3. a presente invenção refere-se a métodos para a purificação de um polipeptídeo que compreende uma região ch2/ch3, compreendendo a ligação do polipeptídeo à proteína a e eluição com um gradiente de ph que começa em um ph baixo.
BR112012004697A 2009-09-01 2010-09-01 método para purificar um polipeptídeo compreendendo uma região ch2/ch3 BR112012004697B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23886709P 2009-09-01 2009-09-01
US61/238,867 2009-09-01
US25343809P 2009-10-20 2009-10-20
US61/253,438 2009-10-20
PCT/US2010/047448 WO2011028753A1 (en) 2009-09-01 2010-09-01 Enhanced protein purification through a modified protein a elution

Publications (3)

Publication Number Publication Date
BR112012004697A2 BR112012004697A2 (pt) 2015-09-08
BR112012004697B1 BR112012004697B1 (pt) 2021-02-09
BR112012004697B8 true BR112012004697B8 (pt) 2021-05-25

Family

ID=43649614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004697A BR112012004697B8 (pt) 2009-09-01 2010-09-01 método para purificar um polipeptídeo compreendendo uma região ch2/ch3

Country Status (14)

Country Link
US (3) US9428548B2 (pt)
EP (2) EP2473617B1 (pt)
JP (1) JP5787891B2 (pt)
KR (1) KR101764449B1 (pt)
CN (2) CN108409829A (pt)
BR (1) BR112012004697B8 (pt)
CA (1) CA2772653C (pt)
ES (1) ES2787234T3 (pt)
HR (1) HRP20200581T1 (pt)
MX (1) MX2012002565A (pt)
PL (1) PL2473617T3 (pt)
RU (1) RU2571929C2 (pt)
SI (1) SI2473617T1 (pt)
WO (1) WO2011028753A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2738499A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
NZ597809A (en) 2009-08-06 2014-05-30 Genentech Inc Method to improve virus removal in protein purification
CA2773428A1 (en) * 2009-09-10 2011-03-17 Lonza Biologics Plc Method and system for polypeptide purification
TR201815709T4 (tr) * 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
JP6420756B2 (ja) * 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
WO2014004103A1 (en) 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
JP6285532B2 (ja) * 2013-03-14 2018-02-28 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質ａに基づくクロマトグラフィを使用するタンパク質純度を増加させる方法
BR112016000231A8 (pt) * 2013-07-12 2019-12-31 Genentech Inc métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos
CN105722523B (zh) * 2013-11-15 2022-06-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
KR101921552B1 (ko) * 2014-03-10 2018-11-23 리히터 게데온 닐트. 사전 세정 단계를 이용하는 면역글로불린 정제
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
DE69023865T2 (de) 1989-07-28 1996-10-17 Wako Pure Chem Ind Ltd Fulgimidderivate.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0602126B1 (en) 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
ES2183131T3 (es) 1996-01-23 2003-03-16 Genentech Inc Anticuerpos anti-cd18 utilizados contra el ictus cerebral.
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2272842C (en) 1996-11-27 2012-05-15 Genentech, Inc. Humanized anti-cd11a antibodies
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
RU2145610C1 (ru) * 1998-12-09 2000-02-20 Общество с ограниченной ответственностью "Протеиновый контур" Способ очистки рекомбинантного эритропоэтина человека
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
SI1189641T1 (sl) 1999-06-25 2009-12-31 Genentech Inc Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2
DE60039448D1 (de) 1999-10-29 2008-08-21 Genentech Inc Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
EP1578774B1 (en) * 2002-09-18 2013-11-06 Danisco US Inc. Purification of immunoglobulins
CN101120017A (zh) * 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 用于纯化抗体的亲和力加离子交换层析
EP1693108A1 (en) 2004-12-04 2006-08-23 MERCK PATENT GmbH Mixed-modal anion-exchange type separation material
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
CA2661872A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080167450A1 (en) 2007-01-05 2008-07-10 Hai Pan Methods of purifying proteins
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
EP2445936A1 (en) * 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
HRP20200581T1 (hr) 2020-07-10
MX2012002565A (es) 2012-05-29
WO2011028753A1 (en) 2011-03-10
RU2571929C2 (ru) 2015-12-27
PL2473617T3 (pl) 2020-06-29
JP2013503877A (ja) 2013-02-04
KR101764449B1 (ko) 2017-08-02
KR20120106719A (ko) 2012-09-26
CN108409829A (zh) 2018-08-17
CA2772653C (en) 2019-06-25
US9428548B2 (en) 2016-08-30
RU2012112536A (ru) 2013-10-10
CN102686738A (zh) 2012-09-19
EP3736338A1 (en) 2020-11-11
JP5787891B2 (ja) 2015-09-30
BR112012004697B1 (pt) 2021-02-09
CA2772653A1 (en) 2011-03-10
EP2473617A1 (en) 2012-07-11
US20220324905A1 (en) 2022-10-13
EP2473617B1 (en) 2020-02-26
US20130041139A1 (en) 2013-02-14
US20220081466A1 (en) 2022-03-17
EP2473617A4 (en) 2014-04-09
ES2787234T3 (es) 2020-10-15
BR112012004697A2 (pt) 2015-09-08
SI2473617T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
BR112012004697B8 (pt) método para purificar um polipeptídeo compreendendo uma região ch2/ch3
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
CR20120371A (es) Antagonistas de pcsk9
BR112013021562A2 (pt) anticorpos para cd70
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
BRPI0702163A (pt) composições de toner e métodos
DK2139987T5 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
BR112013027224A2 (pt) proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112012017051A2 (pt) método para diminuir a imunogenicidade
BR112013000623A2 (pt) purificação de proteína.
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
BRPI0918842A2 (pt) método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
BRPI0919950A2 (pt) método para alijar uma coluna montante com peça de desgaste otimizada
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
BR112012027793A2 (pt) método para a purificação de uma proteína de ligação de cátion divalente, e, kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF